Keynote-057

KEYNOTE-057: Pembrolizumab Monotherapy for High-risk NMIBC Unresponsive to BCG

GU Oncology Now

KEYNOTE-057 Cohort B: pembrolizumab for BCG-unresponsive, high-risk NMIBC

KEYNOTE-057: extended follow-up of pembrolizumab in bladder cancer

Keynote 057 - Pre test, post test and further readings

conference workshop

KEYNOTE-057: Outcomes for Patients With BCG-Unresponsive NMIBC Who Do Not Respond to Pembrolizumab

GU Oncology Now

Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBC

KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients

Dr. Balar Discusses KEYNOTE-057 Study in NMIBC

KEYNOTE-057 cohort C: pembrolizumab with favezelimab or vibostolimab in NMIBC

Dr Li on Patient Outcomes From the KEYNOTE-057 Trial in BCG-Unresponsive NMIBC

Dr. Balar on Rationale for KEYNOTE-057 in NMIBC

Copy of Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBC

Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

Enhancing immunotherapy efficacy in bladder cancer

Estudo KEYNOTE-057: Pembrolizumabe no Câncer de Bexiga não músculo-invasivo refratário

Oncologia Brasil agora é Med IQ

Interview with Dr. Balar

European Association of Urology

Estudo Keynote 057

Dr. Rodrigo Ughini Villarroel

Immune checkpoint inhibitors in urothelial bladder cancer

Management of BCG Unresponsive Cystectomy Ineligible Bladder Cancer Patients Pembrolizumab

Grand Rounds in Urology